Can Patient or Arterial Characteristics Guide the Choice between Carotid Angioplasty and Carotid Endarterectomy? The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) (P01.225)

CONCLUSIONS: Beyond the previously described differential treatment efficacy by age, there were no other patient or arterial characteristic detected to identify patient subgroups that would differentially benefit from the choice of CAS versus CEA. Our inability to identify factors to guide treatment choices could be due to the low number of stroke and death events, incomplete information regarding arterial characteristics in the CEA population, or the potential exclusion of "high risk" groups (such as those with severe arterial tortuosity) from the study.Disclosure: Dr. Moore has nothing to disclose. Dr. Roubin has received royalty payments from Abbott Vascular and Cook Inc. Dr. Rosenfield has received personal compensation for activities with Abbott Vascular, Complete Conf Management, Contego Medical, LLC, and HCRI as a consultant. Dr. Rosenfield has received personal compensation for activities with Abbott, Complete Conference Management, Contego Medical, LLC and HCRI. Dr. Rosenfield has received personal compensation for serving on the Board of Directors of VIVA Physicians. Dr. Rosenfield has received royalty payments from Angiograd (Cordis). Dr. Rosenfield holds stock and/or stock options in Contego Medical, LLC and Medical Simulation Corp. Dr. Rosenfield has received research support from Abbott Vascular. Dr. Altafullah has received personal compensation from Boehringer Ingelheim, Genenteck, Pfizer, Coaxia, AGA Medical, and Atritech....Dr. Altafullah holds stock in Pfize...

Source: Neurology - February 14, 2013 Category: Neurology Authors: Moore, W., Roubin, G., Rosenfield, K., Altafullah, I., Ansel, G., Voeks, J., Meschia, J., Lal, B., Howard, G., Brott, T. Tags: P01 Cerebrovascular Disease I Source Type: research